Abstract Purpose Bone-modifying agents (BMAs) for bone metastases are commonly
prescribed for many years even though randomized clinical trials are only 1–2 years in …

Patients with thyroid cancer (TC) usually have an excellent prognosis; however, 5–10% of
them develop an advanced disease. The prognosis of this subgroup is still favourable if the …

Bone is a common site of metastases, particularly in advanced breast and prostate cancer.
Skeletal related events associated with bone metastases include pathologic fracture, need …

Background There remain questions around the optimal use of bone-modifying agents
(BMAs) in patients with bone metastases from breast and castration-resistant prostate …

Aim: More than half of patients with breast, lung, or prostate cancer who have bone
metastases have evidence of skeletal-related events (SREs). Denosumab is a fully human …

Background In an era of multiple life-prolonging therapies for metastatic castration resistant
prostate cancer (mCRPC), the optimal timing of initiation and duration of antiresorptive bone …

Bone lesions from metastatic solid tumors and multiple myeloma (MM) represent an
important source of morbidity in patients with incurable malignancies. Dysregulation of …

Background The widespread adoption of adjuvant bisphosphonate therapy for
postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast …

Bone metastases are a significant source of morbidity and mortality for patients with breast
and prostate cancer. In this review, we discuss key practical themes regarding the use of …

双膦酸盐和地诺单抗作为骨保护剂, 在乳腺癌骨转移的治疗, 早期乳腺癌辅助治疗等方面具有
良好的临床疗效, 但药物选择和用药具体方案等均不明确. 本文旨在从双膦酸盐 …